Delving into the Latest Updates on OD-07656 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

RIPK2

Action

inhibitors

Mechanism

RIPK2 inhibitors(Serine/threonine-protein kinase RIPK2 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [4]

Active Indication

Colitis, UlcerativeBlau SyndromeCrohn Disease+ [1]

Inactive Indication-

Originator Organization

Odyssey Therapeutics, Inc.Startup

Active Organization

Odyssey Therapeutics, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC). In addition, the study will evaluate the potential of OD-07656 to enhance the therapeutic benefit of vedolizumab when given after OD-07656.

Start Date01 Apr 2025

Sponsor / Collaborator

Odyssey Therapeutics, Inc.Startup

NCT06206811

/ CompletedPhase 1

A Four-part, Phase 1, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of OD-07656 in Healthy, Adult Male and Female Participants

First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single and multiple oral doses to healthy male and female participants in view of treating inflammatory bowel disease (IBD) (including Crohn's disease and ulcerative colitis), Blau syndrome, and spondyloarthritis

Start Date12 Feb 2024

Sponsor / Collaborator

Odyssey Therapeutics, Inc.Startup

100 Clinical Results associated with OD-07656

Login to view more data

100 Translational Medicine associated with OD-07656

Login to view more data

100 Patents (Medical) associated with OD-07656

Login to view more data

100 Deals associated with OD-07656

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 2	-	Odyssey Therapeutics, Inc.Startup	01 Apr 2025
Blau Syndrome	Phase 1	Australia	Odyssey Therapeutics, Inc.Startup	12 Feb 2024
Crohn Disease	Phase 1	Australia	Odyssey Therapeutics, Inc.Startup	12 Feb 2024
Spondylarthritis	Phase 1	Australia	Odyssey Therapeutics, Inc.Startup	12 Feb 2024